<p>Shanghai Henlius Biotech Inc. has announced the dosing of the first patient in a phase 1b/2 clinical study evaluating HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with either HLX07 (a recombinant anti-EGFR humanised monoclonal antibody) or HANSIZHUANG (serplulimab injection) in patients with advanced or metastatic colorectal cancer in mainland China. The study is designed to assess the safety, tolerability, and efficacy of the combination therapies. The trial includes a safety run-in stage with dose escalation, followed by a dose expansion stage. As of the date of the announcement, no results from the study have been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260211-12021811), on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

159859

510660

516500

Reuters

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

HENLIUS

Huaan Hang Seng Biotech ETF

Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer